

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Mosunetuzumab for treating relapsed or refractory follicular lymphoma [ID3931]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were identified during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

A patient expert raised a concern that accessing treatment could be an issue. They asked: 'Would this [treatment] potentially be only available in the larger hospital settings in a small number of locations across the country? How could all eligible patients access this treatment?'

The committee considered this a potential equality issue but noted it is related to implementing guidance in NHS practice and therefore outside of its remit. The committee concluded there are no equality issues that can be addressed in the guidance.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues were identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable. The technology is not recommended.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable. The technology is not recommended.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable. The technology is not recommended.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, in section 3.19 of the draft guidance.

**Approved by Associate Director (name):** Ross Dent

**Date:** 03/01/2023

## Final draft guidance

(when draft guidance issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

A commentator raised a concern that not recommending mosunetuzumab will discriminate against older/frailer patients who due to age and co-morbidity do not have equal access to the full range of standard immunochemotherapy options. Noting that these people have an even greater need for novel therapies earlier in their disease course.

The committee acknowledged that some people have a greater unmet need for new treatment options. It also noted that its recommendation applies all people within the marketing authorisation indication for mosunetuzumab. The committee concluded that this is not an equality issue (FDG section 3.19).

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable – the recommendation has not changed. The technology is not recommended.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable – the recommendation has not changed. The technology is not recommended.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make

to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable – the recommendation has not changed. The technology is not recommended.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 3.19 of the final draft guidance.

**Approved by Associate Director (name):** Ross Dent

**Date:** 05/04/2023